ERBB2 and breast carcinoma: Khan A et al. developed FASN siRNA-Encapsulated Her-2 Targeted Fab’-Immunoliposomes, which enhanced drug targeting for Her-2 positive breast cancer cells, and inhibited tumor cell survival by silencing FASN expression [377].